TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $227 from $194 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 Yorvipath beat but a Skytrofa miss due to foreign exchange headwinds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $230 from $210 at RBC Capital
- Ascendis Pharma price target raised to $307 from $306 at UBS
- Ascendis Pharma price target raised to $290 from $243 at Citi
- Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments